Anti-MIRO2 antibody [RM2077],Abcam,AB322962
What are recombinant multiclonals? Recombinant multiclonals are a mixture of recombinant antibodies co-expressed from a library of heavy and light chains. They offer several advantages including: - The sensitivity of polyclonal antibodies by recognising multiple epitopes - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production View our range of recombinant multiclonal antibodies . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents .
Host
Rabbit
Reactivity
Human, Mouse, Rat
Application
WB, ICC/IF, IHC-P
Platform ID
BAB948290333

Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Product Specifications
Scientific Background
Specifications
NameAnti-MIRO2 antibody [RM2077]
Cat. No.AB322962
HostRabbit
IsotypeIgG
ReactivityHuman, Mouse, Rat
ApplicationWB, ICC/IF, IHC-P
ClonalityMulticlonal
Clone NumberRM2077
Concentration0.453 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only
Scientific Background
Target data Mitochondrial GTPase involved in mitochondrial trafficking (PubMed : 16630562, PubMed : 22396657). Probably involved in control of anterograde transport of mitochondria and their subcellular distribution (PubMed : 22396657). See full target information RHOT2
Category Paths
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Request a product
Please provide the required information below so that we can quickly source your products.
